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Purpose. The results of steroid withdrawal in pan-
creas transplant recipients under tacrolimus immuno-
suppression were analyzed. 
Methods. From July 4, 1994 until April 30, 1998, 147 
pancreas transplantations were performed in 141 pa-
tients, including 126 simultaneous pancreas-kidney 
transplantations, 13 pancreas after kidney transplan-
tation, and 8 pancreas transplantations alone. Base-
line immunosuppression consisted of tacrolimus and 
steroids without antilymphocyte induction. Twenty-
three patients were excluded from analysis because of 
early graft loss in 17 cases, retransplantation in 5 
cases, and simultaneous pancreas-kidney transplanta-
tion after heart transplantation in 1 patient. 
Results. With a mean follow-up of 2.8:t1.1 years 
(range 1.0 to 4.8 years), complete steroid withdrawal 
was achieved in 58 (47%) patients with a mean time to 
steroid withdrawal of 15.2:t8 months (range 4 to 40 
months after transplantation). Of the entire cohort of 
141 patients, overall 1-, 2-, and 4-year patient survival 
rates were 98%, 95.5%, and 86%, respectively. Overall 
1-, 2-, and 4-year graft survival rates were 83%, 80%, 
and 71% (pancreas) and 95%, 91%, and 84% (kidney), 
respectively. Of the 124 patients analyzed for steroid 
withdrawal, 1-, 2-, and 4-year patient survival rates 
were 98%, 97%, and 92%, respectively. Overall 1-, 2-, 
and 4-year graft survival rates were 98%, 91.5%, 83% 
(pancreas) and 97%, 95%, and 91% (kidney). Patient, 
pancreas, and kidney survival rates at 1 year were 
100%,100%, and 98% (off steroids) versus 97%, 91%, and 
96% (on steroids, all NS) and at 4 years were 1000/c, 94%, 
and 95% (off steroids) versus 78%, 68%, and 85% (on 
steroids, P=O.OI, 0.002, and NS, respectively). The cu-
mulative risk of rejection at the time of follow-up was 
76% for patients on steroids versus 74% for patients off 
steroids (P=NS). Seven patients originally tapered off 
steroids were treated for subsequent rejection epi-
sodes, which were all steroid sensitive, and two of 
these seven patients are currently off steroids. Thir-
teen patients received antilymphocyte therapy for ste-
roid-resistant rejection, five of whom are now off ste-
roids. Tacrolimus trough levels were 9.3:t2.4 nglml (off 
steroids) and 9.7:t4.3 (on steroids, P=NS). Mean fast-
ing glucose levels were 98:t34 mgldl (off steroids) and 
110:t41 mgldl (on steroids, P=NS). Mean glycosylated 
hemoglobin levels were 5.2:t0.9% (off steroids) and 
1 Presented at the 25th Annual Meeting of the American Society of 
Transplant Surgeons, May 19-21, 1999, Chicago, IL. 
2 Address correspondence to: Mark L. Jordan, MD, FACS, Division 
of Urologic Surgery, Suite 700, 3471 Fifth Avenue, Pittsburgh, PA 
15213. 
3 Division of Urologic Surgery and Transplantation. 
4 Starzl Transplantation Institute, Department of Surgery. 
6.2:t2.1% (on steroids, P=0.02), and mean serum creat-
inine levels were 1.4:t0.8 mgldl (off steroids) and 
1.7:tl.0 mgldl (on steroids, P=0.02). 
Conclusion. These data show for the first time that 
steroid withdrawal can be safely accomplished in pan-
creas transplant recipients maintained on tacrolimus-
based immunosuppression. Steroid withdrawal is as-
sociated with excellent patient and graft survival with 
no increase in the cumulative risk of rejection. 
The results of pancreas transplantation have improved 
dramatically over the last decade with l-year patient sur-
vival rates greater than 90%, and pancreas graft survival 
rates in simultaneous pancreas-kidney transplantations 
(SPK*) greater than 80% in most centers (1-3). These results 
have continued to improve in large part due to the introduc-
tion of novel immunosuppressive agents, including tacroli-
mus (TAC) and mycophenolate mofetil (MMF). A recent re-
view by Stratta (4) indicated that the majority of pancreas 
transplantations are still performed using antibody induc-
tion therapy with cyclosporine (CsA) based immunosuppres-
sion, but that there is an increasing trend to adopt new drug 
combinations including TAC and MMF with or without an-
tibody induction therapy. We have previously reported our 
initial long-term experience with TAC as baseline immuno-
suppressive therapy for pancreas transplantation without 
antibody induction (3), which was associated with excellent 
graft survival and function. In a more recent analysis of 
pancreas transplantation under TAC, in which adjuvant 
bone marrow administration was studied, we reported 1- and 
3-year SPK graft survival rates of 86% and 80%, respectively 
(5). One of the early concerns associated with the use ofTAC 
was its reported potential for diabetogenicity (6, 7), although 
this is reversible in the majority of cases (8, 9). As a conse-
quence, the use ofTAC for pancreas transplantation has only 
recently been adopted in some centers (3, 5, 10-12). One 
potential advantage of TAC that would be especially well 
suited for pancreas transplant recipients is its now well-
reported association with safe steroid withdrawal in approx-
imately 60% of other solid organ recipients (13-15). Safe 
steroid withdrawal under Neoral or CsA in the pancreas 
transplant population has not been systematically attempted 
and hence not reported except for preliminary experiences in 
a small number of patients (16). In our center, we have 
attempted to withdraw steroids as a part of our standard 
* Abbreviations: AZA, azathioprine; CMV, cytomegalovirus; CyA, 
cyclosporine; HbgA1C' glycosylated hemoglobin; MMF, mycopheno-
late mofetil; PTDM, posttransplantation diabetes mellitus; SCR, se-
rum creatinine; SPK, simultaneous pancreas-kidney transplanta-
tions; TAC, tacrolimus. 
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immunosuppressive protocol in pancreas transplant recipi-
ents since 1994. We now report our overall experience from 
July 4, 1994 to April 30, 1998 with steroid withdrawal in 
pancreas transplant recipients receiving tacrolimus-based 
therapy. The results indicate that steroid withdrawal is safe 
and associated with excellent short- and long-term patient 
survival and graft function with no increased risk of delayed 
rejection episodes or toxicity compared with those patients 
who remain on steroids. 
MATERIALS AND METHODS 
Donor and recipient demographiCS. Between July 4, 1994 and 
April 30, 1998, 147 pancreas transplantations were performed in 141 
patients with a mean recipient age of 4MKR~SKU years (range 27.6 to 
59.3 years). TAC-based immunosuppression was used as primary 
therapy in all patients. There were 126 SPK 13 pancreas after 
previous kidney transplantations (PAK), and 8 pancreas transplan-
tations alone (PTA). The mean donor age was PMKM~ 13.6 years (range 
6.8 to 62.7 years). The mean cold ischemia time for the kidney 
transplants was 16.6:!:4.3 hours and for the pancreas transplants 
17.7:!: 1.2 hours. The mean number ofHLA matches was l.3 ~ 1.1 and 
mismatches 4.3:: 1.2. 
For a meaningful analysis of the results of steroid withdrawaL 
only patients undergoing primary pancreas transplantation with 
graft function beyond 3 months of transplantation were analyzed. 
There were 17 pancreas losses within 3 months of transplantation, 5 
retransplantations, and one SPK after heart transplantation. These 
23 cases were excluded. leaving 124 pancreas transplantations for 
analysis. Of these 124 cases, there were 109 SPK 9 pancreas after 
previous kidney transplantations, and 6 pancreas transplantations 
alone. 
Immunosuppression. All patients received primary TAC-based 
immunosuppression with a steroid·tapering regimen. as described 
previously (3). Antilymphocyte antibody induction was not used. Of 
the 124 patients analyzed, 72 (59'7r) received initial therapy with 
TAC, prednisone, and MMF (CellCept) 1 g b.i.d. TAC, prednisone, 
and azathioprine (AZA) at 2 mg/kg/day was the initial therapy in the 
remaining 52 (41%) patients. AZA and MMF doses were titered to 
maintain a white blood count >SOOO/mm3 and dosage according to 
gastrointestinal side effects in the case of MMF. Patients received 
intravenous TAC at 0.03 to O.OS mg/kg/day for 4 to 6 days postoper-
atively, followed by an initial oral dose of 0.15 mg/kg twice daily. The 
TAC dose was adjusted to achieve target whole blood trough levels of 
20-25 ng/ml in the first 2 weeks after transplantation, lS-20 ng/ml 
by 1 month, 10-1S ng/ml by 3 months. 7-12 ng/ml by 6 months. and 
5-10 ng/ml thereafter. All patients received prophylaxis for pneumo· 
cystitis carinii pneumonia with trimethaprim-sulfamethoxazole. Cy-
tomegalovirus (CMV)-seronegative recipients of CMV-positive organ 
donors had biweekly testing for CMV antigen (pp6S) and were 
treated with a 14-day course of intravenous ganciclovir if CMV 
antigenemia was positive. Routine prophylaxis for CMV was not 
given. 
Steroid withdrawal. Steroids were initiated as 0.5-1 g ofintrave-
nous methylprednisolone intraoperatively followed by a tapering 
steroid regimen over the first 5 postoperative days to 20 mg per day 
of prednisone by postoperative day 6. In the presence of subsequent 
stable graft function, prednisone was tapered by 2.5-5 mg every 2 
weeks with the aim of complete steroid withdrawal with concomitant 
careful monitoring of pancreas and renal graft function. Steroid 
tapering was generally ceased if a rejection episode supervened 
within the first 3 months after transplantation. Some patients con· 
tinued to be weaned off steroids after successful treatment of early 
rejection episodes with high-dose corticosteroids, although steroid 
withdrawal generally proceeded more slowly in this scenario. Of the 
124 patients analyzed. 58 (47%) achieved complete steroid with-
drawal with a mean time to complete steroid withdrawal of 15.2:!:8 
months (range 4 to 40 months). 
Rejection. The diagnosis of acute rejection was suspected in pa-
tients with a > 10'7c increase in baseline serum creatinine (SCR), or 
a rising or sustained increase in serum lipase, or both, as described 
previously (In The presence of rejection was confirmed either by 
fine needle aspiration biopsy of the kidney or pancreas, or core needle 
biopsy of the kidney. or both. Biopsy-confirmed rejection was treated 
with either intravenous methylprednisolone boluses (generally 500 
mg daily x 3 days) or by a tapering steroid recycle (200 mg to 20 mg 
over 6 days). Steroid-resistant rejection episodes were treated with 
antilymphocyte antibody (OKT3 or ATGAM) for 7-14 days. 
Statistical analysis. Patient and donor demographic information 
was summarized using descriptive statistics. For continuous vari-
ables, groups were compared using the standard independent sam-
ple t test. For categorical variables. the chi-square test was applied. 
Patient survival rate was calculated from the date of transplantation 
until death, and allograft survival rate from date of transplantation 
until graft failure or patient death. Survival (event-freel rates were 
calculated using the Kaplan·Meier method. Time-ta-event analysis 
(time to rejection, graft failure. or death) was based on the log-rank 
test. Statistical significance was considered at P<O.OS. 
RESULTS 
Patient and graft survival. The mean follow-up was 
2.8::1.1 years (range 1.0 to 4.8 yearsl. The overa1l6-month 
and 1-. 2-, 3-, and 4-year actuarial patient survival rates for 
all 141 patients were 99'7c, 98'7c, 95.5%, 93o/c, and 86% (Fig. 1). 
Overall 6-month and 1-, 2-, 3-, and 4-year actuarial kidney 
graft survival rates were 95'7c, 95%, 91 %,87%, and 84% (Fig. 
1). Overall pancreas graft survival rates for all 147 cases at 6 
months. I, 2, 3, and 4 years were 85.6%, 83%. 80%, 77%, and 
71%. respectively (Fig. 1l. Of the 141 patients who underwent 
transplantation, 131 (93o/e) are currently alive. There were 
four deaths from cardiac events at 2, 2.5, 3.2, and 3.7 years 
after transplantation; two patients died of sepsis at 0.5 and 
1.8 years after transplantation; one patient died of a cerebral 
vascular accident at 0.9 years after transplant; one patient 
died of posttransplant lymphoproliferative disease at 0.3 
years after transplant; and two patients died with unknown 
etiology at 1.4 and 3.9 years after transplantation. Of those 
124 patients analyzed after steroid withdrawal, 1-, 2-. and 
4-year patient survival rates were 98%, 97%, and 92% (Fig. 
2). In this group, kidney and pancreas graft survival rates at 
1,2, and 4 years were 97% and 98%, 95% and 91%, and 91% 
and 83%, respectively (Fig. 2l. Of the 10 patients who died, 3 
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FIGURE 1. Overall patient, kidney, and pancreas allograft survival 
rates for 147 pancreas transplants. 
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FIGURE 2. Patient. kidney, and pancreas allograft survival rates 
excluding retransplants and graft losses within the first 3 months 
after transplantation. 
had been tapered off steroids (all cardiac deaths) and 7 re-
mained on steroids at the time of death. 
Early graft loss. There were a total of 17 pancreases and 4 
kidneys that were lost within the first 3 months after trans-
plantation. Of the 17 pancreases lost, 7 were due to pancre-
atitis at 4, 8, 8, 8, 8, 12, and 76 days after transplantation; 6 
were lost to allograft thrombosis at 1, 1, 1, 1. 4, and 4 days 
after transplantation; 2 were lost to sepsis at 21 and 22 days 
after transplantation; and 1 was lost due to humoral rejec-
tion at 22 days after transplantation. There were four kid-
neys lost within 3 months of transplantation. Two kidneys 
were lost due to sepsis at 14 and 72 days after transplanta-
tion; one was lost due to thrombosis at 16 days after trans-
plantation; and one was lost to humoral rejection at 12 days 
after transplantation. All patients with graft loss within 3 
months of transplantation were excluded from subsequent 
analysis, because none of these patients had the opportunity 
to be tapered off steroids before graft loss. 
Results of steroid withdrawal. Of the 124 patients ana-
lyzed, 58 (47%) were tapered off steroids completely and 66 
(53%) remained on steroids at the time of this analysis, which 
was completed as of April 30, 1998, providing a minimum of 
I-year follow-up for all patients. The 1- and 4-year patient 
survival rates of the patients off steroids were 100% and 
100% and those still on steroids 97% and 78% respectively 
(P=O.OI; Fig. 3). Actuarial pancreas graft survival rates off 
steroids at 1, 2, and 4 years were 100'7c, 100%, and 94%, 
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FIGURE 3. Patient survival rates comparing those off steroids with 
those on steroids. 
respectively, and the rates of those still on steroids were 9191:, 
83.5%, and 67.5'7c, respectively (P=0.002; Fig. 4). There were 
109 patients with simultaneous kidney transplants who were 
analyzed for steroid withdrawal; 55 (50%) were tapered off 
steroids and 54 remain on steroids. The actuarial 1-,2-, and 
4-year graft survival rates of those kidney transplant recip-
ients off steroids were 98%, 98%, and 95%, respectively, and 
the rates of those remaining on steroids were 96%, 91%, and 
85%, respectively (P=NS; Fig. 5). Of those patients still on 
steroids, prednisone dose is 6.2::t3.7 mg per day (range 2.5 to 
20 mg, median 5 mg per day). A total of seven patients who 
were initially completely weaned off prednisone were re-
started on prednisone at a mean of 12 months (range 7 to 20 
months) after transplantation. Of these seven patients, six 
had biopsies performed for rising SCR and were treated for 
rejection with high-dose corticosteroids. The seventh patient 
was empirically treated for rejection for a decreasing urinary 
amylase. All seven patients responded to steroid therapy for 
treatment of rejection, which was biopsy-proven in six cases. 
Of these six, four had mild rejection (Banff grade lA or IB) 
and two had only borderline rejection. Of the seven patients, 
two have now again been weaned completely off steroids. 
Late allograft loss (>3 months after transplantation). Of 
the 124 patients analyzed for steroid withdrawal, 14 had late 
pancreas loss (Table 1) and 10 late renal allograft loss (Table 
2) beyond 3 months after transplantation. Of the 14 pancreas 
allografts that were lost, 2 patients had been weaned off 
steroids and 12 patients continue on steroids. Nine of the 14 
late pancreas losses were due to rejection at 0.7, 0.7, 0.7, 0.8, 
0.9, 1, 1.1, 1.2, 2. and 2.1 years after transplantation. Three 
pancreas grafts were lost due to death at 0.3, 1.8, and 3.9 
years after transplantation. One graft was lost due to sepsis 
at 0.3 years after transplantation and one due to vascular 
occlusion at 3.6 years after transplantation. Of the 9 pan-
creas allograft losses due to rejection >3 months after trans-
plantation, only one patient had been tapered completely off 
steroids. This patient had been weaned off steroids at 4 
months after transplantation and now has graft survival of 
26 months. Eight of the 9 late pancreas allograft losses (89%) 
occurred in patients who remained on steroids. Of the 10 late 
renal allograft losses, 3 patients had been tapered off steroids 
and 7 patients remain on steroids. Five renal allograft losses 
were due to rejection at 1.3. 1.4.2.9, 3, and 3.7 years after 
transplantation; 4 were due to patient death at 0.3, 1.4, 1.8, 
and 2 years after transplantation; 1 was due to sepsis at 0.4 
100 (57) ~K_@wF __ 
. - . 
ESlF~ ... -----
(34) (19) I 
• a SIaada (....al) 
___ 01 SIaada (no6l) 
40 Trre (yrs) a SIaOOI 01 SIaada 
.. 100% 91% 
al 2 100% B3.!J'A. 
4 9l% 67.!J'A. 
... 
l+------I------r------r----~ 4 
FIGURE 4. Pancreas allograft survival rates comparing those off ste-
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FIGURE 5. Kidney allograft survival rates comparing those off ste-
roids with those on steroids. 
TABLE 1. Causes of pancreas allograft loss (>3 mojO 
Time after OfT On Cause Number transplantation 
steroids steroids Iyr) 
Rejection 9 0.7,0.7,0.8, 8 
0.9, 1, 1.1, 1.2, 
2.2.1 
Death 3 0.3, 1.8, 3.9 0 3 
Sepsis 1 0.3 0 1 
Vascular occlusion 3.6 1 0 
Total 14 2 12 
°n=14. 
TABLE 2. Causes of renal allograft loss (>3 mo)O 
Time after Off On Cause Number transplantatIOn 
sterOlds steroids lyr) 
Rejection 5 1.3, 1.4, 2.9, 3. 2 3 
3.7 
Death 4 0.3, 1.4, 1.8, 2 3 
Sepsis 1 0.4 0 1 
Total 10 3 7 
a n=10. 
years after transplantation. Of the five renal allograft recip-
ients who experienced late graft loss due to rejection, two had 
been weaned off steroids at 8 and 30 months after transplan-
tation, respectively, and these grafts survived to 36 and 44 
months after transplantation, respectively. The remaining 
three renal allograft losses were in patients who remained on 
steroids. 
Rejection. There was no significant difference in the cu-
mulative risk of rejection for patients on or off steroids (Fig. 
6). The rejection-free survival rate in patients off steroids 
was 28% and the rate in those on steroids was 27% at the 
time of follow-up. There was a significant difference in the 
total number of episodes of acute rejection per patient, which 
was 1.0±0.84 in the patients off steroids versus 1.56±1.45 in 
those patients still on steroids (P=0.006). Of those patients 
who had been completely weaned off steroids, the number of 
rejection episodes before weaning was 0.2:::0.79 per patient 
and after weaning was 0.08:::0.17 per patient. Of those pa-
tients who were off steroids by the time of this analysis. only 
three have had late rejection episodes, which were reversed 
by steroid treatment in all patients. In the patients remain-
ing on steroids, four patients have had late rejection at 8-39 
II 
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FIGURE 6. Cumulative risk of rejection in pancreas transplant recip-
ients comparing those ofT steroids with those on steroids. 
months after transplantation. Three of these four patients 
underwent allograft biopsy because of rising SCR. The fourth 
patient was treated for rejection because of a rising serum 
lipase. Of the three patients who underwent biopsy, one had 
moderate rejection <Banff grade II), one had mild to moderate 
rejection (Banff grade IE), one had mild rejection (Banff 
grade IA), and one had minimal to borderline rejection. Three 
of the four patients responded to a steroid recycle. The pa-
tient with moderate rejection required antilymphocyte ther-
apywith OKT3. Overall, 13 patients received antilymphocyte 
therapy (OKT3 in 11, ATGAM in 2) for steroid-resistant 
rejection at some point after transplantation. Of these 13 
patients, 5 have been tapered off steroids with good graft 
function. Of the remaining eight patients who were not ta-
pered off steroids after antilymphocyte therapy, six are alive, 
four with functioning grafts (three kidney only, one kidney 
and pancreas) and two experienced graft loss due to recalci-
trant rejection. 
Graft function and steroid withdrawal. The serum amy-
lase, lipase, glycosylated hemoglobin (HbgA1C)' SCR, fasting 
glucose, and tacrolimus trough levels in those patients with 
functioning grafts are shown in Table 3. There was no sig-
nificant difference in serum amylase, lipase, fasting glucose, 
or TAC trough levels off or on steroids. There was a statisti-
cally significant difference in HbgA1C values in those patients 
tapered off steroids (5.2±0.9%) compared with those still on 
steroids (6.2:::2.1o/C, P=O.02). SCR was also statistically bet-
ter in those patients tapered off steroids (1.4:::0.8 mg/dl) 
compared with those still on steroids (1.7±1.0 mg/dl, 
P=0.02). 
DISCUSSION 
The ultimate goal of pancreas transplantation as a treat-
ment option for type I diabetes is freedom from exogenous 
TABLE 3. Laboratory values of functioning allografts 
Off steroids On steroids 
(n=68) (n=66) P value 
mean:tSD mean:tSD 
Amylase (mg/dl) 75:::56 75:::57 NS 
Lipase (mg/dlJ 150:::238 111:::129 NS 
FK trough levels (ng/mll 9.3:::2.4 9.7=:4.3 NS 
HbAle (%) 5.2=:0.9 6.2=:2.1 0.02 
SCR (mg/dO 1.4=:0.8 1.7::: 1.0 0.02 
Glucose lmg/dll 98:::34 110=41 NS 
• U 
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insulin administration with improvement or disappearance 
of diabetic secondary complications and improved quality of 
life (18-23). That pancreas transplantation has achieved 
widespread acceptance as a safe and effective treatment for 
type I diabetes is reflected in the much improved results 
reported over the last several years, which has been facili-
tated in our center by the use ofTAC as a primary therapy for 
immunosuppression without antilymphocyte induction ther-
apy (3, 5, 24). We have previously reported both the short-
term (24,25) and long-term (3) results of pancreas transplan-
tation under TAC immunosuppression and more recently the 
results of pancreas transplantation with adjuvant bone mar-
row infusion with the intent to procure reduced immunolog-
ical responsiveness (5). Concurrent with this experience, oth-
ers have reported the safe and effective use of TAC for 
pancreas transplantation (10-12). 
One of the important side effects of calcineurin agent-
based immunosuppression (including both TAC and CsA) is 
diabetogenicity. In early reports using TAC in primary renal 
transplantation, the risk of insulin-dependent diabetes after 
transplantation (PTDM) was a justifiable concern (6, 7, 9), 
however, with concomitant dose reduction greater than 80O/C 
of patients experiencing PTDM experience complete reversal 
of this complication (8, 13). However, these early observa-
tions may have led many centers to hesitate in using TAC for 
pancreas transplantation. We have previously reported that 
excellent long-term pancreatic graft function can be achieved 
under TAC immunosuppression without evidence of islet tox-
icity, which has obviated any concern in our center for the 
potential long-term diabetogenicity of this agent in pancreas 
transplantation. Another advantage of TAC that had been 
originally reported in the kidney and liver transplant litera-
ture was the concomitant ability to taper and withdraw ste-
roids in up to 60% of patients with no adverse impact on 
long-term patient or graft survival (13-15, 26). This also has 
been observed with the use of TAC for rescue of refractory 
rejection in renal allograft recipients (27). The potential for 
steroid withdrawal with TAC seemed to us to render this 
agent ideally suited for use in pancreas transplantation, 
where the overall goal is to eliminate the need for insulin 
dependence and avoid the long-term risk of steroid-induced 
complications, which may exacerbate the pre-existing com-
plications of peripheral vascular disease and other target 
organ damage. Therefore, one of our earliest goals was to 
achieve complete steroid withdrawal in the pancreas trans-
plant population. A review of the literature fails to reveal any 
concerted attempt to achieve steroid withdrawal in pancreas 
transplant recipients with conventional CsA immunosup-
pression. The purpose of this study was therefore to analyze 
the safety and efficacy of steroid withdrawal in a large cohort 
of patients undergoing pancreas transplantation under TAC. 
In the current study, a total of 124 pancreas transplant 
recipients were analyzed. Patients who had lost their grafts 
within 3 months of transplant were excluded from this anal-
ysis because they would not have been candidates for com-
plete steroid withdrawal. The results should be interpreted 
bearing this in mind, because they represent the outcome 
after successful engraftment after the first 3 months. Com-
plete steroid withdrawal was achieved in 58 of 124 patients 
(47%) with a mean time to steroid withdrawal of 15.2:::8 
months. Patient and pancreas survival were statistically 
higher in the group of patients who had been tapered com-
pletely off steroids, and this is reflective of the fact that these 
patients were selected on the basis of the absence of signifi-
cant early complications as well as the absence of significant 
rejection episodes before attempted steroid tapering. Signif-
icantly, however, most patients had experienced at least one 
rejection episode before weaning but once weaning was 
achieved, further episodes of rejection were rare. Only seven 
patients who were originally tapered off steroids required 
re-treatment for subsequent rejection, and of these seven, 
two have been tapered off steroids once again. Biochemical 
parameters were identical in both those patients off and on 
steroids except for HbgA1 (, and SCR, which were statistically 
better in the patients off steroids. This is probably reflective 
of the better overall outcome in those patients, which in turn 
facilitated steroid withdrawal in this group. 
Attempts at steroid withdrawal in solid organ transplan-
tation have heretofore been confined to patients undergoing 
kidney, heart, or liver transplantation. The earliest report of 
withdrawal of prednisone in cadaver kidney transplantation 
was published in 1977 by Thaysen and Lokkegaard (28), 
before the CsA era. Steroid withdrawal in the CsA era has 
been reported largely in the European literature but more 
recently has become an area of intense interest in the North 
American literature. In 1988, Stratta et al. (29) reported 
successful steroid weaning in 89% of 25 diabetic recipients of 
living-related renal transplants. Half of these patients sub-
sequently required reinstitution of steroid therapy, but even-
tually 64% of these patients again were rendered steroid free. 
In 1990, Schulak et al. (30) reported the results of a prospec-
tive, randomized trial using CsA maintenance immunosup-
pression with or without maintenance prednisone therapy in 
both cadaver and living-related transplant recipients. Rejec-
tion episodes were more frequent in the non prednisone group 
as was rejection severity. In a series of papers by Hricik et al. 
(31,32), steroid withdrawal in CsA-treated renal transplant 
recipients was analyzed both for the potential salutary ef-
fects on PTDM (31) and lipid metabolism (16). In a small 
series of seven renal transplant recipients with PTDM and 
one recipient of a SPK who exhibited evidence of PTDM, 
seven patients discontinued insulin or oral hypoglycemic 
agents within 4 months of discontinuing steroids (31). In this 
study, mean HbgA1C declined from 10.6::'::3.6% before steroid 
withdrawal to 6.0::: 1.3% within 1 month of steroid cessation 
with concomitant unchanged mean CsA trough levels. In a 
subsequent article designed to predict the outcome of steroid 
withdrawal, Hricik et al. (32) observed that steroid with-
drawal was successful in only 41% of renal transplant recip-
ients in whom prednisone was discontinued in <6 months 
after transplantation, but in 79% of patients in whom pred-
nisone was discontinued >6 months after transplantation. In 
addition to studies of the potential beneficial effect of steroid 
withdrawal on lipoprotein profiles of CsA-treated adult kid-
ney recipients (16), Ingulli et al. reported beneficial effects of 
steroid withdrawal on blood pressure and lipid profile in the 
pediatric population (33). Subsequent studies have also con-
firmed the beneficial effect of steroid withdrawal on lipid 
metabolism, PTDM, and in the case of children, growth and 
development in renal transplant recipients (34, 35). Steroid 
withdrawal has also been reported in the liver transplant 
population by Mazariegos et al. (15), as part of an attempt of 
total weaning of immunosuppression in a select group ofliver 
transplant recipients. 
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Early reports of steroid withdrawal in renal transplant 
recipients receiving CsA concluded that weaning should only 
be attempted at least 6 months after successful transplanta-
tion because of the potential risk for rejection and CsA tox-
icity (32, 34). More recent reports of steroid withdrawal in the 
TAC era have focused on early steroid withdrawal in kidney 
recipients with maintenance of a steroid-free state in the 
long-term in approximately 60% of patients (13, 14, 35, 36). 
We have previously reported in an initial study of 60 pan-
creas transplantations performed under TAC immunosup-
pression that steroid withdrawal was accomplished in 65% of 
those with functioning grafts (3). We have also recently re-
ported the results of adjuvant bone marrow administration to 
53 SPK recipients under TAC immunosuppression, in whom 
67% were steroid free at 3 years (51. Our expanded experi-
ence with steroid withdrawal reported herein has indicated 
that this approach is safe and associated with very little risk 
of late graft loss to rejection. Whether MMF provides an 
added advantage over AZA in terms of the ability to wean 
patients off steroids in this population will require further 
study. Of 52 patients on AZA in the current study, 32 (61 %) 
were weaned off steroids versus 26 (42%) of those on MMF 
(P==NS). Because the mean time to steroid withdrawal in the 
AZA group was 20 months versus 12 months in the MMF 
group (P=O.OOl), the lower incidence of steroid withdrawal in 
the MMF group likely reflects the shorter term follow-up in 
this more recently transplanted group. 
To identifY which pancreas transplant recipients are most 
likely to benefit while at the same time achieve safe steroid 
withdrawal will require prospective randomized trials under 
a strict set of selection criteria. In the current study, patients 
were not randomly assigned to steroid withdrawal and hence 
were a selected group, which may account for the observed 
improved patient and graft survival rates and reduced fre-
quency of rejection episodes per patient in those who were 
withdrawn from steroids compared with those who remained 
on steroids. Nevertheless, this is the first report demonstrat-
ing that steroid withdrawal is safe and can be accomplished 
in approximately 50% of pancreas transplant recipient pa-
tients with acceptable patient and graft survival rates in the 
short- and medium-term. We believe that the steroid sparing 
effects of TAC previously documented in other solid organ 
transplant recipients are also applicable to the pancreas 
transplant population. Whether this steroid-free state will 
further improve the reversal of type I diabetes-induced com-
plications after successful pancreas transplantation will re-
quire further study. 
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